A. Morales and D. Eidinger, Bacillus Calmette-Guerin in the treatment of adenocarcinoma of the kidney, J Urol, vol.115, pp.377-380, 1976.

R. Breban, A. Bisiaux, C. Biot, C. Rentsch, and P. Bousso, Mathematical model of tumor immunotherapy for bladder carcinoma identifies the limitations of the innate immune response, OncoImmunology, vol.119, issue.1, pp.1-9, 2012.
DOI : 10.4161/onci.1.1.17884
URL : https://hal.archives-ouvertes.fr/pasteur-01402054

B. Breart, F. Lemaitre, S. Celli, and P. Bousso, Two-photon imaging of intratumoral CD8+ T cell cytotoxic activity during adoptive T cell therapy in mice, Journal of Clinical Investigation, vol.118, issue.4, pp.1390-1397, 2008.
DOI : 10.1172/JCI34388

Y. Cao, D. Gillespie, and L. Petzold, Efficient step size selection for the tau-leaping simulation method, The Journal of Chemical Physics, vol.124, issue.4, p.44109, 2006.
DOI : 10.1063/1.2159468

A. Bisiaux, N. Thiounn, M. Timsit, A. Eladaoui, and H. Chang, Molecular Analyte Profiling of the Early Events and Tissue Conditioning Following Intravesical Bacillus Calmette-Guerin Therapy in Patients With Superficial Bladder Cancer, The Journal of Urology, vol.181, issue.4, pp.1571-1580, 2009.
DOI : 10.1016/j.juro.2008.11.124
URL : https://hal.archives-ouvertes.fr/pasteur-01402294

A. Cooper, Cell-Mediated Immune Responses in Tuberculosis, Annual Review of Immunology, vol.27, issue.1, pp.393-422, 2009.
DOI : 10.1146/annurev.immunol.021908.132703
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4298253

C. Biot, C. Rentsch, J. Gsponer, F. Birkhauser, and H. Jusforgues-saklani, Preexisting BCG-Specific T Cells Improve Intravesical Immunotherapy for Bladder Cancer, Science Translational Medicine, vol.4, issue.137, pp.137-172, 2012.
DOI : 10.1126/scitranslmed.3003586
URL : https://hal.archives-ouvertes.fr/pasteur-01402032

D. Lamm, B. Blumenstein, J. Crissman, J. Montie, and J. Gottesman, MAINTENANCE BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY FOR RECURRENT TA, T1 AND CARCINOMA IN SITU TRANSITIONAL CELL CARCINOMA OF THE BLADDER: A RANDOMIZED SOUTHWEST ONCOLOGY GROUP STUDY, The Journal of Urology, vol.163, issue.4, pp.1124-1129, 2000.
DOI : 10.1016/S0022-5347(05)67707-5

A. Van-der-meijden, R. Sylvester, W. Oosterlinck, W. Hoeltl, and A. Bono, Maintenance Bacillus Calmette-Guerin for Ta T1 Bladder Tumors Is Not Associated with Increased Toxicity: Results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial, European Urology, vol.44, issue.4, pp.429-434, 2003.
DOI : 10.1016/S0302-2838(03)00357-9

F. Pagano, P. Bassi, C. Milani, A. Meneghini, and D. Maruzzi, A low dose bacillus Calmette-Guerin regimen in superficial bladder cancer therapy: is it effective?, J Urol, vol.146, pp.32-35, 1991.

A. Losa, R. Hurle, and A. Lembo, LOW DOSE BACILLUS CALMETTE-GUERIN FOR CARCINOMA IN SITU OF THE BLADDER:, The Journal of Urology, vol.163, pp.68-71, 2000.
DOI : 10.1097/00005392-200001000-00017

D. Mack and J. Frick, Low-dose bacille Calmette-Guerin (BCG) therapy in superficial high-risk bladder cancer: a phase II study with the BCG strain Connaught Canada, British Journal of Urology, vol.145, issue.Suppl., pp.185-187, 1995.
DOI : 10.1111/j.1464-410X.1995.tb07308.x

J. Martinez-pineiro, N. Flores, S. Isorna, E. Solsona, and J. Sebastian, Long-term follow-up of a randomized prospective trial comparing a standard 81???mg dose of intravesical bacille Calmette-Gu??rin with a reduced dose of 27???mg in superficial bladder cancer, BJU International, vol.37, issue.Suppl. 1, pp.671-680, 2002.
DOI : 10.1046/j.1464-410X.2002.02722.x

A. Ojea, J. Nogueira, E. Solsona, N. Flores, and J. Gomez, A Multicentre, Randomised Prospective Trial Comparing Three Intravesical Adjuvant Therapies for Intermediate-Risk Superficial Bladder Cancer: Low-Dose Bacillus Calmette-Guerin (27 mg) versus Very Low-Dose Bacillus Calmette-Guerin (13.5 mg) versus Mitomycin C, European Urology, vol.52, issue.5, pp.1398-1406, 2007.
DOI : 10.1016/j.eururo.2007.04.062

M. Agrawal, M. Agrawal, S. Bansal, M. Agarwal, and P. Lavania, The Safety and Efficacy of Different Doses of Bacillus Calmette Gu??rin in Superficial Bladder Transitional Cell Carcinoma, Urology, vol.70, issue.6, pp.1075-1078, 2007.
DOI : 10.1016/j.urology.2007.07.017

P. Andius, M. Fehrling, and S. Holmang, Intravesical bacillus Calmette-Guerin therapy: experience with a reduced dwell-time in patients with pronounced side-effects, BJU International, vol.128, issue.9, pp.1290-1293, 2005.
DOI : 10.1016/S0302-2838(03)00048-4

E. De-boer, S. Rooyakkers, D. Schamhart, T. De-reijke, and K. Kurth, BCG Dose Reduction by Decreasing the Instillation Frequency: Effects on Local Th1/Th2 Cytokine Responses in a Mouse Model, European Urology, vol.48, issue.2, pp.333-338, 2005.
DOI : 10.1016/j.eururo.2005.05.004

P. Bassi, R. Spinadin, R. Carando, G. Balta, and F. Pagano, Modified Induction Course: A Solution to Side-Effects?, European Urology, vol.37, issue.Suppl. 1, pp.31-32, 2000.
DOI : 10.1159/000052380

S. Bunimovich-mendrazitsky, E. Shochat, and L. Stone, Mathematical Model of BCG Immunotherapy in??Superficial Bladder Cancer, Bulletin of Mathematical Biology, vol.166, issue.6, pp.1847-1870, 2007.
DOI : 10.1007/s11538-007-9195-z

S. Bunimovich-mendrazitsky, Y. Goltser, S. Bunimovich-mendrazitsky, C. Gluckman, J. Chaskalovic et al., Use of quasi-normal form to examine stability of tumor-free equilibrium in a mathematical model of bcg treatment of bladder cancer, Mathematical Biosciences and Engineering, vol.8, issue.2, pp.529-547, 2011.
DOI : 10.3934/mbe.2011.8.529

S. Bunimovich-mendrazitsky, H. Byrne, and L. Stone, Mathematical Model of Pulsed Immunotherapy for??Superficial Bladder Cancer, Bulletin of Mathematical Biology, vol.166, issue.4, pp.2055-2076, 2008.
DOI : 10.1007/s11538-008-9344-z